BioAtla

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioAtla and other ETFs, options, and stocks.

About BCAB

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. 

CEO
Jay M. Short
CEOJay M. Short
Employees
76
Employees76
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2007
Founded2007
Employees
76
Employees76

BCAB Key Statistics

Market cap
21.93M
Market cap21.93M
Price-Earnings ratio
-0.35
Price-Earnings ratio-0.35
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$0.4051
High today$0.4051
Low today
$0.3647
Low today$0.3647
Open price
$0.3967
Open price$0.3967
Volume
1.38M
Volume1.38M
52 Week high
$1.43
52 Week high$1.43
52 Week low
$0.24
52 Week low$0.24

Stock Snapshot

With a market cap of 21.93M, BioAtla(BCAB) trades at $0.37. The stock has a price-to-earnings ratio of -0.35.

On 2026-01-09, BioAtla(BCAB) stock traded between a low of $0.36 and a high of $0.41. Shares are currently priced at $0.37, which is +1.7% above the low and -8.4% below the high.

BioAtla(BCAB) shares are trading with a volume of 1.38M, against a daily average of 2.53M.

During the past year, BioAtla(BCAB) stock moved between $0.24 at its lowest and $1.43 at its peak.

During the past year, BioAtla(BCAB) stock moved between $0.24 at its lowest and $1.43 at its peak.

People also own

Based on the portfolios of people who own BCAB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.